Lowell is developing an anticoagulant for critically ill patients in the ICU who experience kidney failure and need to go on an artificial kidney machine called continuous renal replacement therapy (CRRT), which is 24/7 dialysis. This machine involves circulating blood outside the patient through a filter. Eventually blood will clot in the filter unless it is anticoagulated. When the filter clogs, doctors and nurses must stop the machine to change it – throwing away clotted blood and in the process, increasing blood loss and need for transfusions.
It is then time consuming for ICU doctors and nurses to re-establish the dialysis circuit. The ideal product provides anticoagulation in the filter but not in the patient, thus the need for developing a regional (versus systemic) anticoagulant.